Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indore SEZ project:...

    Indore SEZ project: Lupin seeks more time from Government to complete project

    Farhat NasimWritten by Farhat Nasim Published On 2019-04-19T09:45:17+05:30  |  Updated On 19 April 2019 9:45 AM IST
    Indore SEZ project: Lupin seeks more time from Government to complete project

    Lupin has requested "for extension of letter of permission (LoP) beyond April 11, 2019, for one year up to April 11, 2020," according to the agenda of the meeting circulated by the ministry.


    New Delhi: Drug firm Lupin has sought more time from the commerce ministry to complete its project, with proposed investment of Rs 205.69 crore, in the Indore Special Economic Zone (SEZ). The company is setting up its pharma unit in Indore SEZ to manufacture pharmaceutical formulations - metered dose inhalers and dry powder inhalers.


    Lupin's plea for extension of time will be considered by the highest decision making the body of SEZs - Board of Approval (BoA) - in its meeting on April 22 here.


    Read Also: Lupin gets USFDA nod to generic version of Prozac tablets


    Lupin has requested "for extension of letter of permission (LoP) beyond April 11, 2019, for one year up to April 11, 2020," according to the agenda of the meeting circulated by the ministry.


    The company received the LoP on April 12, 2016. It has already received two extensions, valid till April 11 this year.


    The Development Commissioner (DC) of Indore SEZ has recommended the company's request to BoA as the "unit has made the expenditure of Rs 43.11 crore till March 28 and the construction activities are in full swing and are expected to be completed by November 2019," it said.


    Read Also: Lupin receives USFDA approval for Testosterone Gel


    It added that the unit has expressed its commitment to commence production before March 2020.


    The company has stated that "the delay in the apportionment of land resulted in delayed start of the project," the agenda said.


    As per SEZ rules, DC is authorised to grant an extension of validity of LoP beyond the second year of the expiry of the original validity. But, it is subject to a condition that two-thirds of the activities including construction relating to setting up of the unit is complete and a chartered engineer's certificate to this effect is submitted by the entrepreneur.


    If these conditions are not met, then the unit has to approach the BoA for seeking more time.


    "In this case, however, the requisite two-thirds activities have not been completed as the unit is still under construction. The unit had submitted the CA certificate," it added.


    Read Also: Lupin launches antidepressant drug Fluoxetine in US market


    SEZs are export hubs and units in these zones enjoy certain tax benefits and single window system for different approvals.

    apportionmentBOABoard of Approvaldose inhalersDrug firm Lupindry powder inhalersgovt of indiaIndoreIndore Special Economic Zoneletter of permissionLOPLupinLupin Limitedlupin SEZmeteredMinistry of CommerceNew Delhipharmapharma newspharma news indiaSEZ indoreSEZs
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok